World News | Carolyn Y Johnson, The Washington Post | Thursday March 10, 2016
When the drug company Novartis launched its breakthrough cancer medicine, Gleevec, in 2001, the list price was $26,400 a year. The company's chief executive acknowledged it was expensive, calling it an "uphill battle to win understanding for our decision."
www.ndtv.com